Meruvax II Side Effects
Generic name: rubella virus vaccine
Note: This document contains side effect information about rubella virus vaccine. Some of the dosage forms listed on this page may not apply to the brand name Meruvax II.
Applies to rubella virus vaccine: subcutaneous powder for injection
The vaccine has rarely been associated with chronic joint symptoms. The incidence of arthritis and arthralgia is generally higher in adult women than in children (women, 12% to 26%; children, 0% to 3%), and symptoms tend to be more marked and of longer duration, persisting for months or years (rare). In adolescent girls, the incidence of reactions appears to be intermediate between those seen in children and in women. These reactions are generally well tolerated and rarely interfere with normal activities, even in women over 35 years old.[Ref]
Musculoskeletal side effects have included arthralgia and/or arthritis (usually transient and rarely chronic), myalgia, paresthesia, and rarely chronic arthritis; these symptoms may also occur with natural rubella.[Ref]
A postmarketing surveillance study of measles/mumps/rubella vaccine in Finland during 1982 to 1993 with 1.5 million pediatric and adult vaccinees reported no deaths or permanent sequelae.[Ref]
Other side effects have included fever, syncope, headache, dizziness, malaise, and irritability. Fatalities have been reported with the polyvalent measles/mumps/rubella vaccine; however, causality has not been determined.
Health care providers should report any allergic or unusual adverse reactions to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 (USA) and the manufacturer.[Ref]
1. "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.
Medically reviewed by Drugs.com. Last updated on June 23, 2020.
More about Meruvax II (rubella virus vaccine)
Related treatment guides
Some side effects may not be reported. You may report them to the FDA.